0
0
Recent research from Rice University has uncovered a surprising new role for opioid receptors—not just in pain management and addiction, but in the very development of the gut’s nervous system. This discovery, published in the journal PLOS ONE, sheds new light on the complex biology of opioids and could have significant implications for the treatment of congenital digestive disorders.
Led by Rosa Uribe, assistant professor of biosciences and a CPRIT Scholar, the research team used zebrafish embryos—which share genetic similarities with humans—to investigate the genes involved in the formation of the enteric nervous system (ENS), often called the “brain in the gut.” By employing gene-editing techniques, the researchers selectively removed genes, including those coding for opioid receptors, and observed the effects on nerve development in the gut.
The results were striking. When opioid receptors were deactivated, the migration and maturation of enteric neurons along the gut were disrupted, indicating that opioid signaling pathways are essential for proper ENS development. This challenges the conventional view that opioid receptors are solely involved in pain perception and addiction.
“We found that the opioid signaling pathway is required for the developmental formation of nerves in the gut, an understudied part of the body called the enteric nervous system,” Uribe explained. “When these receptors were deactivated, the migration and maturation of enteric neurons along the gut were disrupted.” This finding opens up new avenues for understanding digestive health and disease, particularly in infants born with missing or malformed gut nerves, who often struggle with passing stool.
The study also identified other genes, such as VGF, with potential implications for gastrointestinal health. Further research in this area could reveal more about the complex interplay between genes, the nervous system, and digestive function, according to lead researcher and postdoctoral fellow Rodrigo Moreno Campos.
Implications for Medicine and Policy
This research comes at a time when opioid pain medicines remain an important treatment option for severe pain but are subject to strict safety labeling and prescribing guidelines due to risks of misuse, addiction, overdose, and even paradoxical increases in pain sensitivity—a condition known as opioid-induced hyperalgesia (OIH). The FDA has recently updated safety labels for all opioid analgesics to reflect these risks and to provide clearer guidance for prescribers and patients.
While the Rice University findings do not directly address pain management or addiction, they underscore the multifaceted role of opioid receptors in human biology. Understanding their function in gut development could lead to innovative treatments for congenital digestive disorders and further inform the risk-benefit analysis of opioid use, especially in vulnerable populations such as pregnant women and infants.
Looking Ahead
The discovery by Uribe and her team highlights the importance of continued research into the basic biology of opioid receptors. As scientists uncover more about their diverse roles in the body, it may become possible to develop targeted therapies that harness the benefits of opioid signaling while minimizing the risks of misuse and adverse effects.
Disclaimer
This article is based on recent scientific research and official FDA communications. It is intended for informational purposes only and should not be considered medical advice. Consult a qualified healthcare professional for any questions regarding opioid use, pain management, or digestive health. The FDA and other regulatory bodies continue to monitor and update safety information related to opioid medications, and patients should always follow the guidance of their healthcare providers.
